Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in alzheimer's disease: Diverging behavior at three different brain regions

Journal of Alzheimer's Disease

Volumn 36, Issue 1, 2013, Pages 155-163

  Bittner, Daniel M ^a   Heinze, Hans Jochen ^a   Kaufmann, Jörn ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; A ; cerebrospinal fluid; hTau; MR spectroscopy; pTau

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; AMYLOID BETA PROTEIN[1-42]; ASPARTIC ACID; BIOLOGICAL MARKER; CHOLINE; CHOLINESTERASE INHIBITOR; CREATINE; CREATINE PHOSPHATE; GLUCOSE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; GUANINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID; PHOSPHORYLCHOLINE; PHOSPHOYLATED TAU; TAU PROTEIN; TAURINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE SCANNER; PARIETAL GYRUS; PARIETAL LOBE; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RECOGNITION; SENSITIVITY AND SPECIFICITY; SHORT TERM MEMORY; SIGNAL NOISE RATIO; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

EID: 84878825413     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-120778     Document Type: Article

References (52)

1. Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-gerichtliche Medizin 64, 146-148.
2. Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related cortical destruction. Eur Neurol 33, 403-408.
3. (1998) Consensus report of the working group on: Biological Markers of Alzheimer's disease. The Ronald and Nancy Reagen Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19, 109-116.
4. Frank RA, GalaskoD, Hampel H, Hardy J, de Leon MJ,Mehta PD, Rogers J, Siemers E, Trojanowski JQ (2003) Biological markers for therapeutic trials in Alzheimer's disease - proceeding of the Biological MeasuresWorking Group: NIA Initiative on Neuroimaging in Alzheimer's disease. Neurobiol Aging 24, 521-536.
5. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613.
6. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289, 2094-2103.
7. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Alzheimer's disease neuroimag ing initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
8. Baslow MH (2000) Functions of N-acetyl-L-aspartate and Nacetyl-L-aspartylglutamate in the vertebrate brain: Role in glial cell-specific signalling. J Neurochem 75, 453-459.
9. Dautry C,Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, Bloch G, Hantraye P (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20, 789-799.
10. Gasparovic C, Arfai N, Smid N, Feeney DM(2001) Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury. J Neurotrauma 18, 241-246.
11. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W(2006) Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67, 528-530.
12. Krishnan RR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160, 2003-2011.
13. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigang SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR (2004) 1H MR spetroscopy in common dementias. Neurology 63, 1393-1398.
14. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD (2002) Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125, 2332-2341.
15. Satlin A, Bodick N, Offen WW, Renshaw PF (1997) Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: Changes after treatment with xanomeline, an M1 selective cholinergic agent. Am J Psychiatry 154, 1459-1461.
16. Falini A, Bozzali M, Magnani G, Pero G, Gambini A, Benedetti B, Mossini R, Franceschi M, Comi G, Scotti G, FilippiM(2005) A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. NeuroImage 26, 1159-1163.
17. Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in AD. Neurology 56, 592-598.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
19. Folstein MF, Folstein SE, McKugh PR (1975) Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
20. Helmstaedter C, Lendt M, Lux S (2001) Verbaler Lern-und Mekrfähigkeitstest (VLMT) Beltz, Göttingen.
21. Rey A(1941) L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol 28, 286-340.
22. Wechsler D (1997)Wechsler Memory Scale: Revised manual. The Psychological Corporation, San Antonio, TX.
23. Kessels RP, van Zandvoort MJ, Postma A, Kappelle LJ, de Haan EH (2000) The corsi block-tapping task standardization and normative data. Appl Neuropsychol 7, 252-258.
24. Isaacs B, Kennie A (1973) The set test as an aid to the detection of dementia in old people. Br J Psychiatr 123, 467-470.
25. Kaplan E, Goodglass H,Weintraub S (1978) The Boston Naming Test, Veterans Administration Medical Center, Boston.
26. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo protonNMRspectra. Magn Reson Med 30, 672-679.
27. Schuff N, Capizzano AA, Amend DL, O'Neill J, Norman D, Kramer J, Jagust W, Miller B, Wolkowitz OM, Yaffe K, Weiner MW (2002) Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58, 928-935.
28. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D(2001) Cramér-Rao bounds: An evaluation tool for quantitation. NMR Biomed 14, 278-283.
29. Watanabe T, Shiino A, Akiguchi I (2012) Hippocampal metabolites and memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Neurobiol Lern Memory 97, 289-293.
30. Champod AS, Petrides M(2010) Dissociation within the frontoparietal network in verbal working memory: A parametric functional magnetic resonance imaging study. J Neurosci 30, 3849-3856.
31. Fornito A, Harrison BJ, Zalesky A, Simons JS (2012) Competitive and cooperative dynamics of large-scale brain functional networks supporting recollection. Proc Natl Acad Sci U S A 109, 12788-12793.
32. Jessen F, Gür O, Block W, Ende G, Frölich L, Hammen T, Wiltfang J, Kucinski T, Jahn H, Heun R, Maier W, Kölsch H, Kornhuber J, Träber F (2009) A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72, 1735-1740.
33. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, Reyes D, Shiung M, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr. (2007) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28, 1330-1339.
34. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 384, 23-28.
35. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, Wolkowitz OM, Jagust WJ, Chui HC, Miller BL, Yaffe K, Weiner MW (2005) Reduced medial temporal lobe N-acetylasparate in cognitively impaired but nondemented patients. Neurology 64, 282-289.
36. Kantarci K, Jack CR, Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1HMRS study. Neurology 55, 210-217.
37. Hugg JW, Kuzniecky RI, Gilliam FG (1996) Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol 40, 236-239.
38. Jessen F, Lewczuk P, Gür O, Block W, Ende G, Frölich L, Hammen T, Arlt S, Kornhuber J, Kucinski T, Popp J, Peters O, Maier W, Träber F, Wiltfang J (2011) Association of Nacetylaspartate and cerebrospinal fluid A-42 in dementia. J Alzheimers Dis 27, 393-399.
39. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H (2009) Validation of Alzheimer's disease CSF and plasma biological markers: The multicenter reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44, 579-585.
40. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 59, 512-519.
41. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzega A (2009) Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927-934.
42. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P,Wiste HJ,Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
43. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundmann M (2010) 11C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372.
44. Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L (2010) Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord 29, 204-212.
45. Ewers M, Cheng X, Nural HF,Walsh C, Meindl T, Teipel SJ, Buerger K, Shen Y, Hampel H (2011) Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. J Alzheimers Dis 25, 373-381.
46. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN (2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50, 1464-1470.
47. Klunk W, Xu C, Panchalingam K, McClure J, Pettegrew J (1996) Quantitative 1H and 31P MRS of PCA extracts of post-mortem Alzheimer's disease brain. Neurobiol Aging 17, 349-357.
48. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF A-42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656.
49. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP (2007) No association of CSF biomarkers with APOEe4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320-2326.
50. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR (2008) Alzheimer disease: Postmortem neurpathologic correlates of antemortem 1H MR spectroscopy metabolite measurement. Radiology 248, 210-220.
51. Kantarci K, Xu YC, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, BoeveBF, Edland SD,Kokmen E,Tangalos EG, Petersen RC, Jack CR (2002) Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14, 198-207.
52. Chantal S, Labelle M, Bouchard RW, Braun CMJ, Boulanger Y (2002) Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Neurology 59, 955-962.